Cardiovascular adverse events of ibrutinib
- PMID: 31778540
- PMCID: PMC6887111
- DOI: 10.1182/blood.2019002805
Cardiovascular adverse events of ibrutinib
Abstract
In this issue of Blood,
Conflict of interest statement
Conflict-of-interest disclosure: The author declares no competing financial interests.
Comment on
-
Hypertension and incident cardiovascular events following ibrutinib initiation.Blood. 2019 Nov 28;134(22):1919-1928. doi: 10.1182/blood.2019000840. Blood. 2019. PMID: 31582362 Free PMC article. Clinical Trial.
References
-
- Chen J, Kinoshita T, Sukbuntherng J, Chang BY, Elias L. Ibrutinib inhibits ERBB receptor tyrosine kinases and HER2-amplified breast cancer cell growth. Mol Cancer Ther. 2016;15(12):2835-2844. - PubMed
-
- Leong DP, Caron F, Hillis C, et al. . The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138-140. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical